Novavax Ebitda from 2010 to 2024

NVAX Stock  USD 8.04  0.02  0.25%   
Novavax EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA is likely to outpace its year average in 2024. During the period from 2010 to 2024, Novavax EBITDA regression line of annual values had significance of  0.01 and arithmetic mean of (313,713,167). View All Fundamentals
 
EBITDA  
First Reported
1996-03-31
Previous Quarter
179.9 M
Current Value
-134 M
Quarterly Volatility
111.3 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novavax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novavax's main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.3 M, Interest Expense of 15.1 M or Selling General Administrative of 499.1 M, as well as many indicators such as Price To Sales Ratio of 0.47, Dividend Yield of 0.0066 or Days Sales Outstanding of 82.31. Novavax financial statements analysis is a perfect complement when working with Novavax Valuation or Volatility modules.
  
Check out the analysis of Novavax Correlation against competitors.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Latest Novavax's Ebitda Growth Pattern

Below is the plot of the Ebitda of Novavax over the last few years. It is Novavax's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novavax's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Novavax Ebitda Regression Statistics

Arithmetic Mean(313,713,167)
Coefficient Of Variation(134.36)
Mean Deviation276,307,556
Median(161,893,000)
Standard Deviation421,512,234
Sample Variance177672.6T
Range1.7B
R-Value(0.62)
Mean Square Error118757.2T
R-Squared0.38
Significance0.01
Slope(58,050,866)
Total Sum of Squares2487415.9T

Novavax Ebitda History

2024-463 M
2023-487.4 M
2022-604.7 M
2021-1.7 B
2020-411.8 M
2019-138.6 M
2018-165.8 M

About Novavax Financial Statements

Novavax investors use historical fundamental indicators, such as Novavax's Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Novavax. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-487.4 M-463 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.